New data on Dapagliflozin
New data from the EASD provides valuable insights to physicians treating patients with type 2 diabetes
Increased heart problems in women with diabetes
Five million people at risk of developing diabetes
Minority patients under-represented in diabetes trials
Study sheds light on importance of fat stem cells in understanding risk of diabetes
New treatment that improves control of diabetes at mealtimes now available in UK
A new, fast-acting mealtime insulin for adults living with type 1 or type 2 diabetes has been launched in the UK. Fast-acting insulin aspart (Fiasp) is a formulation that more closely matches the natural physiological insulin response of a person without diabetes, after meals, compared with the rapid-acting insulin, insulin aspart (NovoRapid).